Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 635-643

  Bonafede, MacHaon M K ^a   Gandra, Shravanthi R ^b   Fox, Kathleen M ^c   Wilson, Kathleen L ^a  

^a THOMSON REUTERS   (United Kingdom)

^b AMGEN INC   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

Author keywords

Administrative claims data; Dose escalation; Rheumatoid arthritis; TNF blockers

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; YOUNG ADULT;

EID: 84862534500     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.667028     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. 2010. Available at http://www.cdc.gov/arthritis/basics/rheumatoid.htm
2. Enbrel-(etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, CA, USA
3. Humira-(adalimumab) Prescribing Information, Abbott Laboratories, Abbott Park, IL, USA
4. Remicade-(infliximab) Prescribing Information, Centocor, Inc., Malvern, PA, USA
5. Simponi-(golimumab) Prescribing Information, Centocor, Inc., Malvern, PA, USA
6. Cimzia-(certolizumab pegol) Prescribing Information, UCB, Inc., Smyrna, GA, USA
7. Pascual-Salcedo D, et al. Influence of immunogenicity on the efficacy of longterm treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-1452
8. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15
9. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6 (Pubitemid 46999794)
10. Bartelds GM, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
11. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16 (Pubitemid 38530193)
12. Foerder CA, Rogge MC. Enbrel (etanercept). Dev Biol (Basel) 2002; 109:99-102
13. Klareskog L, Moreland L, Cohen S, et al. Efficacy and safety of over 8 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann Rheum Dis 2006;65(Suppl II):326
14. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2010;70:284-8
15. Haraoui B, Cameron L, Ouetliet M, et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-6 (Pubitemid 43054276)
16. Finckh A, Dudier J, Wermelinger F, et al. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010;77:313-18
17. Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken) 2010;62:1335-41
18. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic doseescalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
19. Van Vollenhoven RF, Brannemark S, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry. STURE. Scand J Rheumatol 2007;36:418-23 (Pubitemid 350293517)
20. Pavelka K, Jarosova K, Suchy D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-9
21. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: a comparative effectiveness analysis. ISPOR European Congress, Prague, Czech Republic, November 6-9, 2010 (abstract)
22. Segal SD, Power DJ, Smith DB, et al. Comparative effectiveness analysis of TNF blockers in rheumatoid arthritis (RA) patients in US community practice. EULAR, London, UK, May 25-28, 2011(abstract)
23. Gu NY, Huang XY, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits 2010;2:9
24. Harrison D, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Surg Pathol 2010; 67:1281-7
25. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53 (Pubitemid 44476656)
26. Huang X, Ning G, Fox K, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010; 26:1637-45
27. Ollendorf D, Kingman D, Hazard R, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:821-35
28. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BioMed Central Musculoskeletal Disorders 2008;9:52
29. Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008;30:1939-55
30. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91
31. SAS. Version 9.2. Cary (NC): SAS Institute Inc., 2002-2008
32. Khanna D, Cyhaniuk A, Bedenbaugh A. Use of TNF inhibitors in the US: Utilisation patterns and dose escalation from a retrospective US RA population. EULAR, London, UK, May 25-28, 2011 (abstract)